Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and EBVSTs for EBV-Positive Lymphoma
NCT02973113Phase 1Completed
- Sponsor
- Baylor College of Medicine
- Start
- Feb 2016
- Primary completion
- Sep 2019
- Modality
- Adoptive Cell Transfer
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Epstein-Barr virus specific cytotoxic T lymphocytes in non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL) and lymphoproliferative disorders (LPD), sponsored by Baylor College of Medicine. Primary endpoint: Number of Dose-Limiting Toxicities at 2 months. Started Feb 2016; status: completed.
02
Drugs
Epstein-Barr virus specific cytotoxic T lymphocytes
03
Conditions
non-Hodgkin lymphoma (NHL)Hodgkin lymphoma (HL)lymphoproliferative disorders (LPD)
Beyond the preview
Go deeper on NCT02973113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02973113.